Abbott announced new data from its AVEIR Conduction System Pacing (CSP) study, showing successful implantation of its investigational leadless pacemaker targeting the left bundle branch area of the heart. The study demonstrated that conduction system pacing with the AVEIR leadless device mimics the heart’s natural electrical rhythm and was presented as a late-breaking clinical trial at the Heart Rhythm Society’s 46th annual meeting.

Additionally, Abbott has begun enrolling patients in the ASCEND CSP pivotal clinical trial to evaluate its CSP Implantable Cardioverter-Defibrillator (ICD) lead. The trial will involve up to 414 participants across 70 sites globally. Abbott's UltiPace Pacing Lead, already FDA-approved for left bundle branch area placement, complements its broader CSP strategy. Both the AVEIR CSP system and the CSP ICD lead have received Breakthrough Device Designation from the FDA.

Abbott emphasized that conduction system pacing could improve treatment outcomes for patients with slow or irregular heart rhythms by offering alternatives that preserve the heart’s natural function. The company continues to innovate within cardiac rhythm management to expand treatment options.